Application Number: AU 2026201448
Compositions and methods for detecting Bordetella pertussis nucleic acid
DETAILED DESCRIPTION and detecting Bordetella pertussis and/or Bordetella parapertussis nucleic acid from a sample. The compositions, kits, and methods provide oligonucleotide sequences that recognize target the IS481 and IS1001 gene sequences of B. parapertussis, respectively, or their complementary sequences.
View the Compositions and methods for detecting Bordetella pertussis nucleic acid PDF
Download the PDF version of this Application Open to Public Inspection
ABSTRACT Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for detection of Bordetella pertussis and Bordetella parapertussis nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
The Problem
BACKGROUND The genus Bordetella contains eight species, of which four are known to cause more or less severe respiratory diseases in humans: Bordetella bronchiseptica, holmesii, parapertussis, and pertussis. Bordetella holmesii is less virulent than the other three species (CDC guidance, report 2012; WHO, report 2014). Bordetella pertussis is described as a strictly human pathogen whereas Bordetella parapertussis is found in sheep and humans. Bordetella bronchiseptica can cause respiratory infections in many animal species and, infrequently, in humans. An increasing number of pertussis-like cases are attributed to the emerging pathogen Bordetella holmesii, but it is still unclear whether this species is truly pathogenic to humans (Von Konig et al., 2011; Pittet et al., 2014). Several commercial Several commercial kits kits basedbased on nucleic on nucleic acids detection acids detection are available are available for for Bordetella pertussis and parapertussis detection in clinical specimens (review in Arbefeville S. & Ferrieri P., Optimizing polymerase chain reaction testing for the diagnosis of pertussis; current perspectives, Pathology and Laboratory Medicine International, 2015
In existing solutions, practitioners face limitations in achieving desired outcomes efficiently. This invention directly addresses these gaps by introducing novel technical approaches and mechanisms.
What This Invention Does
DETAILED DESCRIPTION and detecting Bordetella pertussis and/or Bordetella parapertussis nucleic acid from a sample. The compositions, kits, and methods provide oligonucleotide sequences that recognize target the IS481 and IS1001 gene sequences of B. parapertussis, respectively, or their complementary sequences.
The integration of these technical elements creates a system capable of delivering improved performance over existing alternatives. The inventors have identified and implemented solutions to key challenges that have limited previous approaches in this field.
Key Features
Innovative Technical Integration. The system seamlessly combines multiple functional components to work as a coordinated whole, enabling capabilities that would be difficult or impossible with standalone elements.
Dynamic Parameter Management. The invention includes mechanisms for adapting operational parameters based on conditions and requirements, allowing for optimized performance across diverse scenarios.
Enhanced Efficiency and Capability. Through its novel architecture and control mechanisms, the system achieves superior performance metrics compared to conventional approaches in the field.
Who Is Behind It?
Gen-Probe Incorporated has brought this innovation to the patent system with expertise from a skilled team of inventors: EATON, Barbara L.; GROBARCZYK, Benjamin; BARHDADI, Samira. This represents their commitment to advancing technology in this important field.
Why It Matters
This patent application demonstrates significant innovation in an important technical area. The solutions described in the specification have the potential to improve how practitioners approach problems and deliver value in real-world applications.
The international patent classifications include C12Q 1/689 (2018.01). These codes situate the invention within the broader landscape of technological innovation and represent important areas of advancement.
AU 2026201448 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.
Related Concepts
Whooping cough (pertussis) caused by Bordetella pertussis remains a significant public health concern despite widespread vaccination. Rapid, accurate detection using PCR-based nucleic acid amplification tests is critical for outbreak management. Specific oligonucleotide probes targeting insertion sequences such as IS481 provide high sensitivity and specificity in clinical diagnostics.
Related Patents Open to Public Inspections
See related Patents open to public inspection.
Compositions and methods for detecting Bordetella parapertussis nucleic acid
How Full Is the Tube? Gen-Probe’s Differential Fluid Level Measurement System
CLOSTRIDIUM HISTOLYTICUM ENZYMES AND METHODS FOR THE USE THEREOF
Disclaimer
The information presented in this article is provided for general informational and illustrative purposes only.
Content on this page may be derived from publicly available intellectual property records, including patent documentation and related materials. While reasonable care is taken in compiling and summarising this information, ATMOSS does not guarantee the accuracy, completeness, currency, or reliability of any content presented.
This article is not a substitute for reviewing the original source documents. Patent applications, specifications, claims, and related records may contain detailed technical, legal, and contextual information that is not fully represented in this summary.
ATMOSS does not provide legal, technical, or commercial advice. Users should not rely on this content for decision-making purposes.
For authoritative and up-to-date information, users should refer directly to the official records available via IP Australia and other relevant intellectual property databases. Links to these official sources are provided where applicable.
ATMOSS accepts no liability for any loss, damage, or consequences arising from the use of, or reliance on, the information contained in this article.